Acadian Asset Management
TBPH icon

Acadian Asset Management’s Theravance Biopharma TBPH Stock Holding History

Acadian Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.7M Buy
1,276,576
+110,617
+9% +$1.96M 0.03% 375
2025
Q4 		$21.8M Buy
1,165,959
+76,578
+7% +$1.27M 0.04% 320
2025
Q3 		$15.9M Buy
1,089,381
+780,729
+253% +$9.87M 0.03% 372
2025
Q2 		$3.4M Buy
308,652
+134,058
+77% +$1.3M 0.01% 684
2025
Q1 		$1.55M Buy
174,594
+174,451
+121,994% +$1.62M ﹤0.01% 824
2024
Q4 		$1K Sell
143
-69,166
-100% -$629K ﹤0.01% 1581
2024
Q3 		$557K Buy
+69,309
New +$600K ﹤0.01% 1060
2022
Q2 		– Sell
-8,277
Closed -$77K – 1853
2022
Q1 		$77K Buy
8,277
+2,818
+52% +$27.6K ﹤0.01% 1413
2021
Q4 		$60K Sell
5,459
-43,843
-89% -$382K ﹤0.01% 1461
2021
Q3 		$362K Buy
+49,302
New +$551K ﹤0.01% 1140

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management's TBPH Position: Q1 2026 in Review

Acadian Asset Management increased its Theravance Biopharma (TBPH) stake by 9.5% in Q1 2026, buying an estimated $1.96M and bringing the position to 1,276,576 shares worth $20.7M. The position accounts for 0.03% of the portfolio, ranked #375.

Acadian Asset Management first reported a position in TBPH in Q3 2021 and has held it in 10 quarters since. The position peaked at $21.8M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Acadian Asset Management held 1,276,576 shares of Theravance Biopharma worth $20.7M as of Q1 2026.
  • Acadian Asset Management bought 110,617 Theravance Biopharma shares in Q1 2026, an estimated $1.96M.
  • Theravance Biopharma made up 0.03% of Acadian Asset Management's portfolio in Q1 2026, its #375 holding.
  • Acadian Asset Management first reported a position in Theravance Biopharma in Q3 2021 and has held it in 10 quarters since.
  • Acadian Asset Management's Theravance Biopharma position peaked at $21.8M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.